| Autor: |
Nigel A.J. McMillan, Thomas J. Gonda, H. Peter Soyer, Dubravka Skalamera, Paul Leo, Graham Leggatt, Sara McKee, Melinda Christensen, Karin Sedelies, Madison Kelly, Daniel Clarke, Sora Fallaha, Mushfiq Shaikh, Melanie Murrell, Weili Wang, Alexander J. Stevenson, Zay Yar Oo, Max V. Ranall, Fawzi Bokhari, Brian Gabrielli |
| Rok vydání: |
2023 |
| DOI: |
10.1158/1535-7163.22504167.v1 |
| Popis: |
Contains siRNA primary screen analysis and subsequent supplemental analyses; Figure S1 Analysis was performed using customized R scripts and proceeded via a three step process; Figure S2 Summary of Z scores of the top 54 selected target hits from the primary screen were rescreened using OnTarget Plus siRNAs; Figure S3 Mitosis is not a general target in HPV-transformed cancer cell lines; Figure S4A. Dose response for all the cell lines with the Aurora B inhibitor ZM447439; Figure S4B. Flow cytometry of the DNA content of cells were treated with 5 μM ZM447439 and collected at 24, 48, and 72 h, using DMSO as a control; Figure S5: Either wild type or K14E7 transgenic skin grafted onto wild type mice, either treated with Alisertib in vivo or untreated, was stained for mast cells using touluidine blue; Figure S6: Alisertib treatment of HPV-transformed cancer cells promotes apoptosis; Figure S7A. HPV- and non-HPV-transformed cancer cells were treated with 5 μM Alisertib and sampled at intervals over 72 h and analysed by flow cytometry for DNA content; S7B. Immunofluorescence of representative HPV-transformed (HeLa) and non-HPV C33A cells treated with DMSO (Control) or 5μM of Alisertib for 48 h stained for DNA and microtubules (α-tubulin). S7C. Quantitation of bi-nucleated and multinucleated cells in control and Alisertibtreated cells for 1 and 2 days; Figure S8 Representative time-lapse series of HeLa and C33A with and without 5 μM Alisertib treatment transiting mitosis and undergoing apoptosis; Figure S9: The time lines for 50 HeLa and 50 CaSki cells treated with 5 μM Alisertib; Figure S10: The dose response of parental HeLa cells and HeLa cells over expressing either Bcl-2 or Mcl- 1 with etoposide and Taxol, respectively, are shown; Figure S11: HPV-transformed ME180 and non-HPV C33A cells were treated with 5 μM Alisertib for up to 3 days; Figure S12 Dose response curves for HPV16 E7 expressing C33A and SCC25 cell lines determined (one of four replicate experiments); Figure S13: FACS of the GFP levels in the HPV18 E7-IRES-GFP transduced SCC25 cell lines used in Figure 7B, C. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
